These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 19689327)

  • 41. Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.
    Iwata Y; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Plitman E; Chung JK; Mar W; Gerretsen P; Pollock BG; Mulsant BH; Rajji TK; Mamo DC; Graff-Guerrero A
    J Clin Psychiatry; 2016 Dec; 77(12):e1557-e1563. PubMed ID: 28086010
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine.
    Schmitt GJ; Meisenzahl EM; Dresel S; Tatsch K; Rossmüller B; Frodl T; Preuss UW; Hahn K; Möller HJ
    J Psychopharmacol; 2002 Sep; 16(3):200-6. PubMed ID: 12236625
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of dopamine D(2) receptors for antipsychotic activity.
    Ginovart N; Kapur S
    Handb Exp Pharmacol; 2012; (212):27-52. PubMed ID: 23129327
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanism of new antipsychotic medications: occupancy is not just antagonism.
    Grunder G; Carlsson A; Wong DF
    Arch Gen Psychiatry; 2003 Oct; 60(10):974-7. PubMed ID: 14557141
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder--implications for psychopharmacology.
    Kasper S; Tauscher J; Willeit M; Stamenkovic M; Neumeister A; Küfferle B; Barnas C; Stastny J; Praschak-Rieder N; Pezawas L; de Zwaan M; Quiner S; Pirker W; Asenbaum S; Podreka I; Brücke T
    World J Biol Psychiatry; 2002 Jul; 3(3):133-46. PubMed ID: 12478878
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
    Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
    Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome.
    Wulff S; Pinborg LH; Svarer C; Jensen LT; Nielsen MØ; Allerup P; Bak N; Rasmussen H; Frandsen E; Rostrup E; Glenthøj BY
    Schizophr Bull; 2015 Sep; 41(5):1143-52. PubMed ID: 25698711
    [TBL] [Abstract][Full Text] [Related]  

  • 48. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder.
    Potkin SG; Keator DB; Kesler-West ML; Nguyen DD; van Erp TG; Mukherjee J; Shah N; Preda A
    CNS Spectr; 2014 Apr; 19(2):176-81. PubMed ID: 24073841
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study.
    Busatto GF; Pilowsky LS; Costa DC; Ell PJ; Verhoeff NP; Kerwin RW
    Psychopharmacology (Berl); 1995 Jan; 117(1):55-61. PubMed ID: 7536945
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?
    Reynolds GP
    J Psychopharmacol; 2021 Sep; 35(9):1030-1036. PubMed ID: 34256637
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia.
    Reynolds GP
    Acta Psychiatr Scand Suppl; 1994; 380():36-40. PubMed ID: 7914046
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol.
    Küfferle B; Tauscher J; Asenbaum S; Vesely C; Podreka I; Brücke T; Kasper S
    Psychopharmacology (Berl); 1997 Oct; 133(4):323-8. PubMed ID: 9372530
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies.
    Abi-Dargham A; Laruelle M
    Eur Psychiatry; 2005 Jan; 20(1):15-27. PubMed ID: 15642439
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The dopaminergic hypothesis revisited].
    Guillin O
    Encephale; 2006 Oct; 32(5 Pt 4):S908-11; discussion S912. PubMed ID: 17119503
    [No Abstract]   [Full Text] [Related]  

  • 55. Molecular imaging of schizophrenia: Neurochemical findings in a heterogeneous and evolving disorder.
    Cumming P; Abi-Dargham A; Gründer G
    Behav Brain Res; 2021 Feb; 398():113004. PubMed ID: 33197459
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dose and dosing frequency of long-acting injectable antipsychotics: a systematic review of PET and SPECT data and clinical implications.
    Uchida H; Suzuki T
    J Clin Psychopharmacol; 2014 Dec; 34(6):728-35. PubMed ID: 24781442
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action.
    Sanyal S; Van Tol HH
    J Psychiatr Res; 1997; 31(2):219-32. PubMed ID: 9278187
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Receptor occupancy and antipsychotic drug action measured by PET and SPECT].
    Okubo Y; Suhara T
    Seishin Shinkeigaku Zasshi; 2001; 103(4):329-40. PubMed ID: 11392846
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.
    Graff-Guerrero A; Mamo D; Shammi CM; Mizrahi R; Marcon H; Barsoum P; Rusjan P; Houle S; Wilson AA; Kapur S
    Arch Gen Psychiatry; 2009 Jun; 66(6):606-15. PubMed ID: 19487625
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.
    Uchida H; Kapur S; Mulsant BH; Graff-Guerrero A; Pollock BG; Mamo DC
    Am J Geriatr Psychiatry; 2009 Mar; 17(3):255-63. PubMed ID: 19225277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.